Ophthalmology · Encino, CA
NPI
1194732578
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
16661 Ventura Blvd Ste 211
Encino, CA, 91436
Phone (818) 205-1200
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
15,799 services
Medicare patients, 2024
1,492
Average age 76
Drug cost, 2024
$1.4M
7,612 prescriptions
Company payments, 2025
$601
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John G Rezapour was code 92025 (test - miscellaneous), 2,168 times for 1,425 patients. In total John G Rezapour billed 15,799 services in 71 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-03-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92025 Test - Miscellaneous | Office | 2,168 | 1,425 | $29.04 | $63K |
| 92250 Angiography | Office | 2,133 | 1,416 | $30.49 | $65K |
| 68761 Eye | Office | 1,964 | 816 | $90.00 | $177K |
| 92014 Ophthalmological E&M | Office | 1,550 | 1,045 | $100.74 | $156K |
| 92134 Computerized Ophthalmic Imaging | Office | 1,416 | 987 | $30.71 | $43K |
| 92020 Ophthalmological E&M | Office | 919 | 665 | $22.23 | $20K |
| 92012 Ophthalmological E&M | Office | 750 | 428 | $72.02 | $54K |
| 92133 Computerized Ophthalmic Imaging | Office | 697 | 458 | $27.57 | $19K |
| 92285 Standard X-ray | Office | 511 | 495 | $19.66 | $10K |
| 99204 Office E&M - New | Office | 471 | 471 | $125.86 | $59K |
| 67938 Eye | Office | 450 | 435 | $338.13 | $152K |
| 92081 Vision, Hearing, and Speech Services | Office | 449 | 449 | $24.56 | $11K |
| 67031 Eye | Office | 318 | 226 | $314.41 | $100K |
| 66821 Cataract Surgery | Office | 295 | 212 | $137.29 | $41K |
| 76519 Ultrasound - Nonspecific | Office | 278 | 133 | $27.82 | $7,733 |
By year: 2022 $1.2M for 12,942 services; 2023 $1.3M for 14,923 services; 2024 $1.3M for 15,799 services.
Medicare prescription drug claims, 2024
In 2024, the drug John G Rezapour prescribed most often to Medicare patients was Cyclosporine, with 972 prescriptions and refills. In total John G Rezapour wrote 7,612 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cyclosporine Generic | 972 | 1,242 | 271 | $325K |
| Erythromycin Erythromycin Base | 879 | 917 | 588 | $8,353 |
| Prednisolone Acetate Generic | 689 | 951 | 421 | $23K |
| Tobramycin-Dexamethasone Tobramycin/Dexamethasone | 675 | 765 | 496 | $21K |
| Restasis Cyclosporine | 489 | 557 | 149 | $319K |
| Latanoprost Generic | 443 | 552 | 105 | $2,702 |
| Simbrinza Brinzolamide/Brimonidine Tart | 373 | 479 | 95 | $76K |
| Ketorolac Tromethamine Generic | 279 | 361 | 154 | $3,581 |
| Cromolyn Sodium Generic | 203 | 347 | 88 | $3,005 |
| Timolol Maleate Generic | 170 | 222 | 41 | $2,185 |
| Xiidra Lifitegrast | 166 | 174 | 67 | $116K |
| Prolensa Bromfenac Sodium | 151 | 179 | 81 | $51K |
| Moxifloxacin Moxifloxacin Hcl | 145 | 147 | 105 | $3,054 |
| Dorzolamide Hcl Generic | 117 | 168 | 33 | $1,416 |
| Lumigan Bimatoprost | 117 | 141 | 28 | $40K |
Brand drugs: 4,163 claims; generic drugs: 3,449 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John G Rezapour $601 ($601 in general payments such as food, travel and fees) from 7 companies. The largest payer was Tarsus Pharmaceuticals, Inc. with $370.
| Company | Payments | Amount |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. TARS | 17 | $370 |
| Alcon Vision LLC ALC | 2 | $59.63 |
| Amgen Inc. AMGN | 2 | $46.8 |
| Oyster Point Pharma, Inc. | 2 | $40.78 |
| Bausch & Lomb Americas Inc. BLCO | 2 | $35.07 |
| Dompe US, Inc. | 1 | $34.5 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 1 | $13.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.